Retatrutide for metabolic diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Insulin Resistance

Why this status

  1. 11 May 2021: Trial registered, NCT04881760
  2. 20 May 2021: Trial started, NCT04881760

The trials

NCT04881760: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

State
Completed
Phase
Phase 2
People
338 taking part
Started
20 May 2021
Primary completion
16 May 2022
Arms
1 milligram (mg) LY3437943, 4 mg LY3437943 (2 mg), 4 mg LY3437943, 8 mg LY3437943 (2 mg), 8 mg LY3437943 (4 mg), 12 mg LY3437943 (2 mg)
Results
Posted on the registry
  1. 11 May 2021: Trial registered
  2. 20 May 2021: Trial started
  3. 22 Nov 2022: Trial completed
  4. 13 Sep 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.